In addition to altered AR-activity, prostate cancers frequently present with genetic alterations in cell cycle and cell death pathways including Ras/Raf/MEK/ERK, JAK/STAT and PI3K/AKT or deregulated pRb, p16, p53, PTEN, Bcl2 and related factors [5], [6], [7], [8]. This evidence concerns the gene TP53 and prostate carcinoma.